TAS-119 | m-entrepreneurship.com

Product Name :
TAS-119

Search keywords :
TAS-119

drugId :
null

Target Vo:
Serine/threonine-protein kinase Aurora-A

Target Vo Short Name :
AURKA

Moa_Name:
Serine/threonine-protein kinase Aurora-A inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Taiho Pharmaceutical Co Ltd

Active Company_Name :
Jiesiyingda Pharmaceutical Technology (Suzhou) Co Ltd

Active Indication_Name:
Leukemia

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 2 Clinical

China Highest Status:
Phase 1 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
PI 3 Kinase p85 alpha Rabbit mAb Purity
Hsp40 Mouse mAb Cancer
LXR alpha Antibody: LXR alpha Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 50 kDa, targeting to LXR alpha. It can be used for WB,ICC,IHC-P,FC assays with tag free, in the background of Human, Mouse, Rat.

Author: Betaine hydrochloride

Related Posts